Wall Street brokerages expect BioTelemetry Inc (NASDAQ:BEAT) to post $0.27 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for BioTelemetry’s earnings, with estimates ranging from $0.24 to $0.30. BioTelemetry reported earnings per share of $0.16 in the same quarter last year, which suggests a positive year over year growth rate of 68.8%. The company is expected to announce its next earnings report after the market closes on Wednesday, May 2nd.
On average, analysts expect that BioTelemetry will report full year earnings of $1.28 per share for the current financial year, with EPS estimates ranging from $1.13 to $1.55. For the next financial year, analysts expect that the company will post earnings of $1.50 per share, with EPS estimates ranging from $1.31 to $1.85. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover BioTelemetry.
BioTelemetry (NASDAQ:BEAT) last issued its quarterly earnings data on Thursday, February 22nd. The medical research company reported $0.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The business had revenue of $91.70 million during the quarter, compared to analysts’ expectations of $88.33 million. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The company’s revenue for the quarter was up 69.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.23 EPS.
Several brokerages have recently issued reports on BEAT. BidaskClub raised BioTelemetry from a “hold” rating to a “buy” rating in a report on Tuesday, April 17th. Zacks Investment Research cut BioTelemetry from a “hold” rating to a “sell” rating in a report on Wednesday, January 31st. TheStreet cut BioTelemetry from a “b-” rating to a “c” rating in a report on Tuesday, March 20th. Finally, Dougherty & Co reissued a “buy” rating and issued a $41.00 price objective (up previously from $40.00) on shares of BioTelemetry in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. BioTelemetry currently has a consensus rating of “Buy” and a consensus target price of $43.00.
Shares of BEAT stock opened at $34.50 on Thursday. The stock has a market capitalization of $1,129.05, a PE ratio of 39.66, a P/E/G ratio of 1.70 and a beta of 0.86. The company has a quick ratio of 1.66, a current ratio of 1.77 and a debt-to-equity ratio of 0.80. BioTelemetry has a 52-week low of $23.30 and a 52-week high of $39.20.
In other news, insider Fred Broadway sold 54,158 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total value of $1,850,578.86. Following the completion of the transaction, the insider now owns 64,880 shares of the company’s stock, valued at approximately $2,216,949.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 9.60% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sterling Capital Management LLC acquired a new position in BioTelemetry in the 4th quarter worth about $12,910,000. MetLife Investment Advisors LLC acquired a new position in BioTelemetry in the 4th quarter worth about $397,000. Lyon Street Capital LLC raised its holdings in BioTelemetry by 2,368.9% in the 4th quarter. Lyon Street Capital LLC now owns 379,029 shares of the medical research company’s stock worth $11,333,000 after purchasing an additional 363,677 shares during the period. Macquarie Group Ltd. raised its holdings in BioTelemetry by 8,866.8% in the 4th quarter. Macquarie Group Ltd. now owns 756,263 shares of the medical research company’s stock worth $22,612,000 after purchasing an additional 747,829 shares during the period. Finally, Vident Investment Advisory LLC acquired a new position in BioTelemetry in the 4th quarter worth about $612,000. 87.13% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “BioTelemetry Inc (BEAT) Expected to Post Earnings of $0.27 Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/22/biotelemetry-inc-beat-expected-to-post-earnings-of-0-27-per-share.html.
BioTelemetry Company Profile
BioTelemetry, Inc, a mobile and wireless medical technology company, provides cardiac and mobile blood glucose monitoring (BGM), centralized medical imaging, and original equipment manufacturing services for the healthcare and clinical research industries. It operates in three segments: Healthcare, Research, and Technology.
Get a free copy of the Zacks research report on BioTelemetry (BEAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.